Table 2_MIND diet score and its association with metabolic dysfunction-associated steatotic liver disease and gut microbiota profiles: a cross-sectional study.docx حسب Shengbo Yang (295144)

Table 1_The RNA-binding protein ProQ directly binds and regulates virulence genes in enterohemorrhagic Escherichia coli O157:H7.docx حسب Ye Qian (7400186)

Table 2_Epidemiological trends and disparities in iodine, vitamin A, and iron deficiencies among children aged 0–14 years globally, 1990–2021.docx حسب Fang Peng (327071)

Table 1_Epidemiological trends and disparities in iodine, vitamin A, and iron deficiencies among children aged 0–14 years globally, 1990–2021.doc حسب Fang Peng (327071)

Table 1_Body Mass Index mediates the associations between dietary approaches to stop hypertension and obstructive sleep apnea among U.S. adults.docx حسب Songtao Li (186776)

Image 1_Body Mass Index mediates the associations between dietary approaches to stop hypertension and obstructive sleep apnea among U.S. adults.tiff حسب Songtao Li (186776)

Image 2_Body Mass Index mediates the associations between dietary approaches to stop hypertension and obstructive sleep apnea among U.S. adults.tiff حسب Songtao Li (186776)

Table 2_Body Mass Index mediates the associations between dietary approaches to stop hypertension and obstructive sleep apnea among U.S. adults.docx حسب Songtao Li (186776)

Data extraction information. حسب Siyuan Chen (200219)

"…Meta-analysis suggested a significant superiority of biologic agents in prolonging relapse-free survival, increasing glucocorticoid taper rate, and decreasing cumulative glucocorticoids dose for both GCA and TAK. …"

ROB 2.0 for RCT. حسب Siyuan Chen (200219)

"…Meta-analysis suggested a significant superiority of biologic agents in prolonging relapse-free survival, increasing glucocorticoid taper rate, and decreasing cumulative glucocorticoids dose for both GCA and TAK. …"

All studies identified in the literature search. حسب Siyuan Chen (200219)

"…Meta-analysis suggested a significant superiority of biologic agents in prolonging relapse-free survival, increasing glucocorticoid taper rate, and decreasing cumulative glucocorticoids dose for both GCA and TAK. …"

Supplemental data for "<b>Kidney cell response to acute cardiorenal and isolated kidney ischemia-reperfusion injury</b>" in Physiological Genomics حسب Kevin Burfeind (20421194)

"…<p dir="ltr">Acute cardiorenal syndrome (CRS) represents a critical intersection of cardiac and renal dysfunction with profound clinical implications. Despite its significance, the molecular underpinnings that mediate cellular responses within the kidney during CRS remain inadequately understood. …"

Table1_Optimizing active recovery strategies for finger flexor fatigue.xlsx حسب Dominika Krupková (20418212)

Table_1_Insights into the salt levels in bread offers in Slovenia: trends and differences.docx حسب Saša Kugler (20554580)

Supplementary Material for: Effect of Amla extract on Body Mass Index, waist circumference, total body fat, visceral fat, skeletal muscle mass, body age and related parameters: A r... حسب figshare admin karger (2628495)

"…Results: Supplementation with 1 gram of AMX-160 (500 mg twice daily) significantly (p<0.05) reduced visceral fat, increased skeletal muscle mass, and decreased subcutaneous fat. …"

Table 4_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

"…</p>Results<p>Testing revealed distinct genomic profiles of lung adenocarcinoma and squamous cell carcinomas and detected variants with a current targeted therapy or clinical trial in >72% of patient tumors. Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"

Table 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

"…</p>Results<p>Testing revealed distinct genomic profiles of lung adenocarcinoma and squamous cell carcinomas and detected variants with a current targeted therapy or clinical trial in >72% of patient tumors. Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"

Table 5_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

"…</p>Results<p>Testing revealed distinct genomic profiles of lung adenocarcinoma and squamous cell carcinomas and detected variants with a current targeted therapy or clinical trial in >72% of patient tumors. Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"

Table 2_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

"…</p>Results<p>Testing revealed distinct genomic profiles of lung adenocarcinoma and squamous cell carcinomas and detected variants with a current targeted therapy or clinical trial in >72% of patient tumors. Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"

Table 3_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

"…</p>Results<p>Testing revealed distinct genomic profiles of lung adenocarcinoma and squamous cell carcinomas and detected variants with a current targeted therapy or clinical trial in >72% of patient tumors. Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"